Synthetic Biology: The Risks and Rewards of Programmable Life

Synthetic biology — the design and construction of new biological parts, devices, and systems — has moved from laboratory curiosity to industrial and clinical reality in roughly a decade. The convergence of cheap DNA synthesis, AI-assisted protein design (AlphaFold), and CRISPR gene editing has dramatically accelerated what is possible.

What Is Working

The pharmaceutical applications of synthetic biology are moving fastest. Engineered microorganisms are producing artemisinin (antimalarial drug), insulin, and a growing range of therapeutics more efficiently than traditional methods. CAR-T cell therapies — where patient immune cells are genetically engineered to target cancer — have produced remarkable results in blood cancers that were previously untreatable. CRISPR-based treatments for sickle cell disease and beta-thalassemia received FDA approval in December 2023, representing the first approved CRISPR therapeutics.

Beyond medicine, synthetic biology is advancing toward: biodegradable plastics produced by engineered organisms, sustainable biofuels, nitrogen-fixing crops (which could dramatically reduce agricultural fertilizer use), and biosensors for environmental monitoring.

AlphaFold's Impact

DeepMind's AlphaFold 2 solved the 50-year protein folding problem — predicting a protein's 3D structure from its amino acid sequence. The subsequent release of predicted structures for all known proteins (over 200 million) has accelerated drug discovery and synthetic biology protein design in ways that are still being understood. AlphaFold 3 (2024) extended this to protein-DNA and protein-small molecule interactions.

The Biosecurity Risk

The same tools that enable therapeutic breakthroughs also lower barriers to biological harm. The primary concern is not nation-state bioweapons programs (which existed before synthetic biology) but the democratization of capabilities: a sufficiently skilled individual or small group with access to DNA synthesis services, gene editing tools, and AI-assisted sequence design could, in principle, engineer more dangerous pathogens than were accessible to non-state actors previously.

The pandemic demonstrated the catastrophic downside risk of biological threats. The COVID-19 outbreak — regardless of its origin — illustrated how rapidly a novel pathogen can propagate globally and overwhelm health systems. A deliberately engineered pathogen designed for transmissibility and lethality represents a catastrophic tail risk that has received serious attention from biosecurity researchers.

Current Safeguards

Safeguards include: DNA synthesis provider screening (companies like Twist Bioscience and Integrated DNA Technologies screen orders against pathogen sequences), biosafety level (BSL) lab requirements for work with dangerous pathogens, select agent regulations, and export controls on certain biological materials. These safeguards have significant gaps: screening is voluntary, jurisdictions vary, and AI-generated sequences may not match existing screening databases.

What Governance Requires

The gap between synthetic biology's capability growth and its governance is widening. The most credible proposals involve: mandatory universal DNA synthesis screening (including for AI-generated sequences), international coordination on dangerous pathogen research, and AI developer agreements to not assist in pathogen design. The technical feasibility of robust screening is improving; the political coordination to implement it universally is not.